Tommaso Stefanelli

Statistics

Publications

Citations

892

H-Index

Active since

2007

Affiliations

Novartis (Switzerland)(Current)

Tel Aviv University

Bambino Gesù Children's Hospital

Incyte (United States)

Novartis (United States)

Tommaso Stefanelli is an author at Novartis (Switzerland) specializing in pharmacotherapy, gastrointestinal inflammation, and inflammatory bowel disease.

Publications per year

2007–2025

Publications

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

Robert Zeiser, Nicola Polverelli, Ron Ram et al. · New England Journal of Medicine · 2021 · 499 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and Clostridium difficile Infection

Shomron Ben‐Horin, Maya Margalit, Peter Bossuyt et al. · Clinical Gastroenterology and Hepatology · 2009 · 140 citations

Veterinary Medicine, Immunology, Pharmacotherapy +17

Critical role of the CD40–CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease

Silvio Danese, Franco Scaldaferri, Stefania Vetrano et al. · Gut · 2007 · 84 citations · Full text

Life Sciences, Immunology, Pathology +17

Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection

Shomron Ben‐Horin, Maya Margalit, Peter Bossuyt et al. · Journal of Crohn s and Colitis · 2009 · 83 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +16

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, Nicola Polverelli, Ron Ram et al. · Blood · 2020 · 37 citations

Life Sciences, Clinical Sciences, Pharmacotherapy +12

1–5 of 9